Higher expectations for management of heart failure: Current recommendations

Journal of the American Board of Family Practice

Volumn 15, Issue 1, 2002, Pages 39-49

  Abraham, William T ^a,d   Scarpinato, Len ^b,c  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c Racine Family Practice Center   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUMETANIDE; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; LISINOPRIL; LOOP DIURETIC AGENT; METOPROLOL; QUINAPRIL; RAMIPRIL; TORASEMIDE; TRANDOLAPRIL;

ALGORITHM; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE CLASSIFICATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARBAZOLES; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; PROGNOSIS; PROPANOLAMINES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 0036158194     PISSN: 08938652     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Deedwania PC. Prevalence and prognosis of heart failure. Cardiol Clin 1994;12:1-8.
2. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999;83:1A-38A.
3. Kannel WE. Need and prospects for prevention of cardiac failure. Eur J Clin Pharmacol 1996;49(Suppl 1):S3-S9.
4. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800-6.
5. Rich MW, Brooks K, Luther P. Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center: 1990-1995. Am Heart J 1998:135:367-72.
6. Philbin EF, Rocco TAJr, Lindenmuth NW, Ulrich K, Jenkins PL. Clinical outcomes in heart failure: report from a community hospital-based registry. Am J Med 1999;107:549-55.
7. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13:S107-12.
8. Heart and stroke statistical update. American Heart Association. Dallas: The Association, 1999.
9. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121:(3 Pt 1)951-7.
10. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994; 72(2 Suppl):S3-9.
11. NHLBI report of the Task Force on Research in Heart Failure. Springfield, Va: Department of Health and Human Services, 1994.
12. Konstam MA, Dracup K, Baker DW, et al. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. J Card Fail 1995; 1:183-7.
13. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764-84.
14. The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Eur Heart J 1997;18:736-53.
15. Cohn JN. The management of chronic heart failure [comments appear in N Engl J Med 1997;336:295-6]. N Engl J Med 1996;335:490-8.
16. Packer M, Bristow MR, Cohn JN, et al. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
17. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353: 9-13.
18. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
19. The effect of digoxin on mortality and morbidity in patients with heart failure. Digitalis Investigation Group. N Engl J Med 1997;336:525-33.
20. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329:1-7.
21. Armstrong PW, Moe GW. Medical advances in the treatment of congestive heart failure. Circulation 1993;88:2941-52.
22. McCall D. Congestive heart failure. In: Stein JH, Hutton JJ, Kohler PO, et al, editors. Internal medicine, 4th ed. St. Louis, Mo: Mosby, 1994:116-31.
23. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
24. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials [published erratum appears in JAMA 1995;274:462]. JAMA 1995;273:1450-8.
25. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: a randomised trial - Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
26. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
27. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998;41(1 Suppl 1):39-52.
28. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-16.
29. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
30. Braunwald E. Expanding indications for beta-blockers in heart failure. N Engl J Med 2001;344:1711-2.
31. Beta-blockers for heart failure. Med Lett Drugs Ther 2000;42:54-5.
32. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314: 1547-52.
33. Fowler MB, Vera-Llonch M, Oster G, et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol 2001;37:1692-9.
34. Luzier et al. Reimbursement claims database analysis of economic and clinical outcomes with carvedilol and metoprolol use in a heart failure population. Presented at the American Society of Managed Care Pharmacy, ? October 2000 San Diego, Calif.
35. Kannel WB. Need and prospects for prevention of cardiac failure. Eur T Clin Pharmacol 1996;49(Suppl 1):S3-9.
36. Heart and stroke statistical update, 2000. Dallas: American Heart Association, 2000.
37. McDermott MM, Feinglass J, Lee P, et al. Heart failure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center [published erratum appears in Am Heart J1998 May; 135(5 Pt 1):924]. Am Heart J 1997;134(5 Pt 1): 901-9.
38. Rich MW, Brooks K, Luther P. Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center: 1990-1995. Am Heart J 1998:135:367-72.
39. Nohria A, Chen YT, Morton DJ, Walsh R, Vlasses PH, Krumholz NM. Quality of care for patients hospitalized with heart failure at academic medical centers. Am Heart J 1999;137:1028-34.
40. Roe CM, Motheral BR, Teitelbaum F, Rich MW. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J 1999;138(5 Pt 1):818-25.
41. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease [published erratum appears in Am J Cardiol 1999;84:1143]. .Am J Cardiol 1999;83: 1303-7.